T

Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867

Watchlist Manager
Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867
Watchlist
Price: 8.19 CNY 0.12% Market Closed
Market Cap: 16B CNY
Have any thoughts about
Tonghua Dongbao Pharmaceutical Co Ltd?
Write Note

Gross Margin
Tonghua Dongbao Pharmaceutical Co Ltd

77.3%
Current
79%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
77.3%
=
Gross Profit
1.9B
/
Revenue
2.4B

Gross Margin Across Competitors

Country CN
Market Cap 16.2B CNY
Gross Margin
77%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 749.1B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 348B USD
Gross Margin
69%
Country US
Market Cap 251.1B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 150.1B USD
Gross Margin
71%
No Stocks Found

Tonghua Dongbao Pharmaceutical Co Ltd
Glance View

Market Cap
16.2B CNY
Industry
Pharmaceuticals

Nestled in the bustling heart of China's pharmaceutical industry, Tonghua Dongbao Pharmaceutical Co., Ltd. has carved out a distinctive niche in the world of diabetes care. Since its inception, the company has been focused on developing, manufacturing, and distributing a range of innovative pharmaceutical products, primarily concentrating on insulin products. With its headquarters strategically located in Tonghua City—a region known for its rich medicinal resources—the company integrates advanced biotechnological processes with traditional pharmaceutical practices. Tonghua Dongbao’s competitive edge lies in its ability to harness cutting-edge technology to produce high-quality insulin products efficiently, allowing it to tap into the rapidly growing domestic and international markets. As diabetes continues to be a major global health challenge, this focus on insulin has positioned the company as a critical player in the fight to manage and treat this chronic disease. Their revenue model is underscored by a keen focus on the production of insulin and its analogs, which represent a significant portion of its sales. Beyond insulin, Tonghua Dongbao also produces a range of other pharmaceuticals, contributing to a diversified product portfolio that supports steady revenue streams. Importantly, the company’s investment in R&D has led to a robust pipeline of new and improved therapeutics aimed at expanding their reach and maintaining competitive advantage. Through strategic partnerships and collaborations, both within China and internationally, Tonghua Dongbao continues to amplify its market presence. In doing so, it exemplifies a commitment not only to financial growth but also to advancing healthcare outcomes for millions of diabetes patients around the globe.

Intrinsic Value
10.11 CNY
Undervaluation 19%
Intrinsic Value
Price
T

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
77.3%
=
Gross Profit
1.9B
/
Revenue
2.4B
What is the Gross Margin of Tonghua Dongbao Pharmaceutical Co Ltd?

Based on Tonghua Dongbao Pharmaceutical Co Ltd's most recent financial statements, the company has Gross Margin of 77.3%.